Cidara Therapeutics (Cidara Therapeutics) Cash per Share : $6.36 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Cidara Therapeutics's Cash per Share for the quarter that ended in Mar. 2024 was $6.36.

Cidara Therapeutics Cash per Share Historical Data

The historical data trend for Cidara Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cidara Therapeutics Cash per Share Chart

Cidara Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash per Share

Get a 7-Day Free Trial

29.71

16.01

17.59

9.03

7.90

Cidara Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash per Share	Get a 7-Day Free Trial															10.66	11.18	10.77	7.90	6.36

Cidara Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Cidara Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	35.778	/	4.53
	=	7.90

Cidara Therapeutics's Cash per Share for the quarter that ended in Mar. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	29.018	/	4.56
	=	6.36

Cidara Therapeutics (NAS:CDTX) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Cidara Therapeutics Cash per Share Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cidara Therapeutics (Cidara Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (NAS:CDTX) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

20D:Germany

Address

6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121

Website

https://www.cidara.com

Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.

Executives

Leslie Tari	officer: Chief Scientific Officer	C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR SUITE 101, SAN DIEGO CA 92121
Taylor Sandison	officer: Chief Medical Officer	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jeffrey Stein	director, officer: President & CEO	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Shane Ward	officer: CHIEF LEGAL OFFICER	C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Preetam Shah	officer: CFO & CBO	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Paul Daruwala	officer: Chief Medical Officer	6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Brady Johnson	officer: Dir. of Finance & Controller	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Timothy R Franson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Carin Canale-theakston	director	C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR STE 101 CA 92121
Bonnie L Bassler	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
James E. Levine	officer: Chief Financial Officer	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Theodore R Schroeder	director	12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Chrysa Mineo	director	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
David L Gollaher	director	6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Daniel D Burgess	director	C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121